{"id":"W4379276081","doi":"10.33380/2305-2066-2023-12-2-146-153","title":"Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC \"PROMOMED RUS\", Russia)","year":2023,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Drug-Induced Hepatotoxicity and Protection","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Pharmacokinetics; Pharmacology; Drug; Medicine; Favipiravir; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000703559,0.0009417013,0.0009098913,0.0002618823,0.0003117188,0.0005313392,0.0005285423,0.0006605132,0.002778702],"category_scores_gemma":[0.0004563122,0.0004429788,0.0006852144,0.0002309207,0.0004337946,0.0004022831,0.0002073834,0.001391007,0.001005814],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004645005,"about_ca_system_score_gemma":0.001179482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004677445,"about_ca_topic_score_gemma":0.0006081582,"domain_scores_codex":[0.9995891,0.0001536239,0.00001577605,0.0001095021,0.00007092935,0.00006111402],"domain_scores_gemma":[0.9998091,0.00002477123,0.00004415528,0.00003009435,0.00003187035,0.00006011564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2286219,0.03851314,0.004931172,0.001254971,0.0008250221,0.0002774246,0.0003813354,0.003674962,0.565324,0.001136797,0.008236168,0.1468231],"study_design_scores_gemma":[0.07778823,0.6100774,0.0279811,0.0001415491,0.001017302,0.002239667,0.0001288382,0.005959515,0.2272876,0.0005781527,0.04665701,0.0001436],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708754,0.004654942,0.0106697,0.0004001018,0.0002821177,0.005255166,0.002497726,0.0007138574,0.004650871],"genre_scores_gemma":[0.966458,0.003217717,0.01062785,0.000794841,0.0001527997,0.004375188,0.004884234,0.0001514342,0.009337976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002778702,"threshold_uncertainty_score":0.009295702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1664712180694004,"score_gpt":0.4490068162313977,"score_spread":0.2825355981619972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}